Compare PEB & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEB | IOVA |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | 52 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | 2008 |
| Metric | PEB | IOVA |
|---|---|---|
| Price | $18.21 | $4.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $13.30 | $9.00 |
| AVG Volume (30 Days) | 3.2M | ★ 13.6M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $47.74 |
| Revenue Next Year | $2.25 | $40.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.30 | $1.70 |
| 52 Week High | $19.75 | $5.63 |
| Indicator | PEB | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 54.04 | 53.73 |
| Support Level | $13.77 | $3.78 |
| Resistance Level | $19.68 | $4.35 |
| Average True Range (ATR) | 0.51 | 0.34 |
| MACD | -0.25 | 0.00 |
| Stochastic Oscillator | 26.54 | 45.67 |
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,052 rooms across 44 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.